PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of f1000medLatest ContentReportsReportsReports
 
F1000 Med Rep. 2009; 1: 54.
Published online 2009 July 8. doi:  10.3410/M1-54
PMCID: PMC2948307

Treatment advances in Alzheimer's disease based on the oxidative stress model

Abstract

Effective therapy for Alzheimer's disease (AD), up to this point, has been hampered by our inability to diagnose the disease in its early stages, before the occurrence of significant neurodegeneration and clinical symptoms. Because AD historically has been defined by neuropathologic criteria, treatment strategies have been aimed at diminishing the pathologic end result of the disease process, namely neurodegenerative changes associated with extracellular amyloid-beta-containing plaques, as well as intracellular neurofibrillary tangles of the hyper-phosphorylated microtubule protein, tau. While these avenues continue to be pursued, results thus far have been disappointing. It is now understood that oxidative stress plays a key role in the shared pathophysiology of neurodegenerative diseases and aging. For experimental treatment of AD, the focus of research and development efforts is increasingly shifting to target mechanisms of oxidative stress. Most recently, dimebon, whose mechanism of action relates to improved mitochondrial function, has emerged as a promising candidate for experimental treatment of AD.

Introduction and context

While Alzheimer's disease (AD) has been defined largely through molecular mechanisms of neuronal dysfunction, there is growing evidence indicating that oxidative stress and reactive oxygen species (ROS) contribute to dementia. Oxidative stress refers to cellular damage mediated by toxic ROS, the formation of which is due to an imbalance between ROS production and the capacity for removing ROS. ROS normally are produced as part of well-characterized metabolic pathways of oxidative phosphorylation during cellular respiration. Free radicals, generally unstable and highly reactive, are removed by specific detoxifying enzymes. With age, increased metabolic demand, and diseases (including AD), there is increased oxidative insult, heightened superoxide radical formation, and increased superoxide dismutase levels which may cause H2O2 to diffuse through the mitochondrial membrane to the cytoplasm. Most free radicals are produced by mitochondria, and mitochondrial abnormalities in AD have been associated with deficiencies of the enzymes of the Krebs cycle, which may either increase free-radical production or alter the mechanism for their clearance [1-5]. Redox-active transition metals aberrantly accumulate in AD-susceptible neurons [6], and increased cytoplasmic H2O2, in the presence of redox-active metals and amyloid-beta (Aβ), may cause localized increased ROS concentration [7-9]. Increased ROS results in oxidation of lipids and RNA.

Studies suggest that there are multiple mechanisms by which oxidative stress may accumulate and create dysfunctional neuronal responses in AD and that development of the AD phenotype requires multiple insults [10-12]. Ischemia, inflammation, and aging are all pro-oxidant conditions. The brain, with its high oxygen use and a consumption of approximately 10% of cardiac output, depends on a number of cellular and tissue-specific antioxidant mechanisms for removal of the resultant by-product of ROS. When these mechanisms are ineffective or dysregulated, there is characteristic cellular injury.

The blood-brain barrier (BBB), critical to normal neuronal function (including synaptic transmission, remodeling, angiogenesis, and neurogenesis [13]), is also substantially compromised in a subpopulation of AD patients [14]. This may be a consequence of endothelial cell injury and dysfunction. One result may be impaired Aβ transport to and from the brain via the receptor for advanced glycation endproducts (RAGE) and transcytosis of Aβ into the brain parenchyma, where it binds to neurons and may enhance formation of toxic ROS.

Current treatment options

The current drugs approved by the US Food and Drug Administration (FDA) to treat AD are the acetyl-cholinesterase (AChE) inhibitors, such as donepizil, and the N-methyl-d-aspartate (NMDA) receptor antagonist, memantine. These drugs are aimed at symptomatic improvement in cognitive ability and are marginally effective [15,16]. The AChE inhibitors are designed to enhance cholinergic neurotransmission by reducing breakdown of acetylcholine (ACh) in the synaptic cleft. The benefit of AChE inhibitors is thought to relate to the role of ACh in memory and the prominent degeneration of basal forebrain cholinergic neurons in AD [17]. Despite its limited clinical efficacy, AChE inhibition has been successful for over 20 years as the best available treatment strategy for AD. More recently, memantine has been FDA-approved for treating AD. Memantine is the first in a class of NMDA receptor antagonists that influence neurotransmission to provide marginal improvement in memory formation and cognitive function in AD [18].

Other psychotropic medications are also used to treat AD patients symptomatically. With moderate to advanced AD, patients frequently become agitated or develop psychotic symptoms such as paranoid ideation and auditory hallucinations. These symptoms often are improved with psychotropic medications, including atypical antipsychotics [19,20] such as risperidone and olanzapine, and typical antipsychotics such as haloperidol [19-21]. These antipsychotic medications, though often helpful, unfortunately carry the risk of precipitating cerebrovascular accidents in older people [22]. Similar to the AChE inhibitors and NMDA receptor antagonists, the antipsychotic agents do not retard progression of the neurodegenerative process. Benzodiazepines sometimes are used, particularly in the acute setting, to treat agitated patients with AD and are also sometimes prescribed for insomnia, as circadian rhythms are frequently disrupted in AD. Although the benzodiazepines are sometimes helpful due to their anxiolytic and sedating properties, it is usually best to avoid using them because they can exacerbate cognitive impairment [23,24].

Recent advances

Redox-active compounds

The advances in the molecular and pathogenetic mechanisms that evolve into the final pathologic picture of AD provide enormous insight into possible targets for newer, and hopefully more effective, therapy. Extracts of Ginkgo biloba show antioxidant properties with reduced superoxide release in polymorphonuclear leukocytes [25]. Ginkgo constituents may act as scavengers of free radicals [26] and increase cholinergic transmission in the brain by inhibiting AChE [27], both of which may be beneficial in AD. However, clinical studies of Ginkgo have not consistently yielded positive results.

A randomized placebo-controlled trial using antioxidant therapies alpha-tocopherol, selegiline, and combination therapy showed significant delays in time to death, placement in a nursing home, development of severe dementia, or a defined severity of impairment of activities of daily living [28]. Antioxidants may ablate cognitive decline [29,30], suggesting that these strategies are beneficial in reducing the risk for developing AD. On the other hand, the beneficial effects of alpha-tocopherol and selegiline and other antioxidants have not always been reproduced in clinical trials [31]. It is possible that the oxidative stress pathophysiology in AD is so severe that conventional antioxidants have marginal or insufficient power to buffer against pathophysiologic redox metabolism. At the present time, antioxidant therapy is not recommended in AD, although patients frequently are advised by physicians to take over-the-counter antioxidant supplements, partly due to the low probability that these compounds will have adverse effects.

Iron chelation

Chelation therapy offers another strategy for reducing oxidative stress. Formation of the toxic hydroxyl radical from H2O2 requires electron donation from Cu+ or Fe2+, the latter being much more prevalent in the labile pools of cytosolic redox-active metals. In the context of AD, the Aβ peptide is considered a strong redox-active agent that is capable of reducing transition metals in the cytoplasm and allowing the conversion of molecular oxygen to H2O2 [9,32,33]. The metal ion dyshomeostasis in AD, with high levels of redox-active metals (particularly iron) being found in the affected areas of the brain, suggests chelation as a reasonable form of therapy. The use of covalent conjugation of nanoparticles with iron chelators [34] has been proposed to help overcome the limitation to chelation therapy imposed by BBB permeability. This unique approach would enable transport of chelators and chelator-metal complexes in both directions across the BBB.

Non-redox-active compounds

Numerous other compounds under development for experimental treatment of AD do not directly quench ROS through redox activity but are known to have downstream antioxidant effects. There is epidemiologic evidence that homocysteine is an independent risk factor for the development of dementia [35], with a plasma level of greater than 14 μM causing a twofold increased risk of AD. A number of studies, however, show that the central nervous system (CNS) is acutely sensitive to homocysteine, which is also an NMDA receptor agonist that stimulates calcium influx and promotes glutamate excitotoxicity, and causes oxidative stress and DNA damage. With its redox-active thiol residues, homocysteine can also impair the antioxidant activities of glutathione. In addition, with its ability to coordinate copper, homocysteine can promote one-electron transfer reactions with H2O2, resulting in the formation of the toxic hydroxyl radical. Elevated plasma homocysteine and low folate may be risk factors for the development of dementia and AD, spurring controlled studies on the efficacy of folate supplementation and reduction of homocysteine levels on dementia and AD [36,37].

Other compounds that have antioxidant effects and that have been tested for efficacy in treating cognitive decline include estrogen replacement, which was shown not to be effective in treating post-menopausal AD. In experimental studies, leuprolide, a selective gonadotropin-releasing hormone agonist that markedly reduces secretion of the gonadotropins, luteinizing hormone, and follicle-stimulating hormone, is thought to divert Aβ protein precursor and reduce brain amyloid and ROS formation [38]. Luteinizing hormone is found to be elevated in AD due to the negative feedback stimulation by low gonadal steroid levels. In clinical studies, female AD patients treated with leuprolide showed stabilization of cognitive impairment and activities of daily living.

Leptin is a centrally acting hormone that controls AMP kinase, maintains lipid levels, and regulates glycogen synthase kinase 3, which modulates tau phosphorylation. Leptin has been shown in vitro and in vivo to reduce extracellular Aβ and neuronal tau phosphorylation as well as improve cognitive performance of transgenic mouse models of AD. In humans, weight loss preceding the onset of AD dementia is inversely proportionate in severity to leptin levels, suggesting that leptin deficiency contributes to systemic and CNS abnormalities in AD and that this hormone may be a novel therapeutic agent in AD, with antioxidant effects through its modulation of intracellular signaling cascades [39].

Insight into the role of metabolic agents, which are influenced by underlying genetics, has emerged. There is a significant increased risk of developing AD in people who have the gene for apolipoprotein E4 (ApoE4), a protein that helps carry circulating cholesterol. A specific fragment formed rapidly from ApoE4 plays a role in oxidative stress by adversely affecting mitochondrial function. It is thought also that poor glucose use and insulin resistance, as seen in type 2 diabetes mellitus, play a role in AD [40,41]. Preliminary results with the oral hypoglycemic agent rosiglitazone in patients with mild to moderate AD show that patients who do not carry the ApoE4 gene show improvement whereas patients with ApoE4 do not respond [42].

We are cautiously optimistic about the potential therapeutic value of dimebon, a new candidate therapeutic agent for AD. Dimebon has been shown to inhibit degeneration of neurons and works through a novel mechanism of action, improving mitochondrial function. In a phase II randomized double-blind placebo-controlled trial with mild to moderate AD, dimebon-treated patients showed statistically significant improvement in cognition, activities of daily living, behavior, and overall function [43]. It was found to have a positive impact on caregiver stress, reducing the amount of time they needed to spend assisting patients. It also showed a favorable side-effect profile. Larger scale clinical trials of dimebon are clearly warranted.

Implications for clinical practice

While cholinesterase inhibitor and NMDA receptor antagonists such as memantine, alone or in combination, continue to be prescribed for patients with AD along with the promotion of proper nutrition and occupational health [44], we feel we are on the threshold of a new era in AD therapy in which therapies will slow the rate of disease progression. Even for those who still believe that the aim of therapy should be to reduce the pathologic end result that characterizes the disease, the hormone leptin shows promise in reducing extracellular Aβ, and the use of covalently conjugated nanoparticles with iron chelators to solubilize Aβ may overcome the limitations of chelation therapy posed by the BBB. Leuprolide therapy, and especially its temporal relationship to menopause, may prove to be the treatment of choice in preventing AD in women. Most of all, the relationship between vascular and cognitive health and the role played by the presence of glucose intolerance on first one and then the other are yielding a new and exciting approach to AD therapy, which may be mechanistically based in oxidative stress. With improved understanding of AD pathogenesis, there is little doubt that the focus of AD therapy will shift to target what appears to be a key player in disease evolution, namely oxidative stress. In this respect, promising compounds like dimebon warrant further development.

We have come a long way in our treatment strategies for AD. Acknowledging that it is the molecular mechanisms instrumental in the evolution of the disease, not the final pathologic result [45], that should be the target is a very big step in a promising direction. This is a very exciting time for the field of Alzheimer's research and should prove fruitful.

Acknowledgments

Work in the authors' laboratories is supported by the National Institutes of Health (R01 AG026151 and R01 AG031852) and the Alzheimer's Association. MWM is supported by the NEURAD PhD Graduate School, a Marie-Curie fellowship awarded by the European Union.

Abbreviations

amyloid-beta
ACh
acetylcholine
AChE
acetyl-cholinesterase
AD
Alzheimer's disease
ApoE4
apolipoprotein E4
BBB
blood-brain barrier
CNS
central nervous system
FDA
US Food and Drug Administration
NMDA
N-methyl-d-aspartate
RAGE
receptor for advanced glycation endproducts
ROS
reactive oxygen species

Notes

The electronic version of this article is the complete one and can be found at: http://F1000.com/Reports/Medicine/content/1/54

Notes

Competing interests

MAS is a paid consultant and/or receives lecture fees from Anavex Life Sciences Corp (Geneva, Switzerland), Medivation (San Francisco, CA, USA), and Neurotez (Bridgewater, NJ, USA).

References

1. Russell RL, Siedlak SL, Raina AK, Bautista JM, Smith MA, Perry G. Increased neuronal glucose-6-phosphate dehydrogenase and sulfhydryl levels indicate reductive compensation to oxidative stress in Alzheimer disease. Arch Biochem Biophys. 1999;370:236–9. doi: 10.1006/abbi.1999.1404. [PubMed] [Cross Ref]
2. Mastrogiacomo F, Bergeron C, Kish SJ. Brain alpha-ketoglutarate dehydrogenase complex activity in Alzheimer's disease. J Neurochem. 1993;61:2007–14. doi: 10.1111/j.1471-4159.1993.tb07436.x. [PubMed] [Cross Ref]
3. Moreira PI, Siedlak SL, Wang X, Santos MS, Oliveira CR, Tabaton M, Nunomura A, Szweda LI, Aliev G, Smith MA, Zhu X, Perry G. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol. 2007;66:525–32. doi: 10.1097/01.jnen.0000240476.73532.b0. [PubMed] [Cross Ref]
4. Simonian NA, Hyman BT. Functional alterations in Alzheimer's disease: selective loss of mitochondrial-encoded cytochrome oxidase mRNA in the hippocampal formation. J Neuropathol Exp Neurol. 1994;53:508–12. doi: 10.1097/00005072-199409000-00010. [PubMed] [Cross Ref]
5. Yates CM, Butterworth J, Tennant MC, Gordon A. Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J Neurochem. 1990;55:1624–30. doi: 10.1111/j.1471-4159.1990.tb04948.x. [PubMed] [Cross Ref]
6. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A. 1997;94:9866–8. doi: 10.1073/pnas.94.18.9866. [PubMed] [Cross Ref]
7. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem. 2000;74:270–9. doi: 10.1046/j.1471-4159.2000.0740270.x. [PubMed] [Cross Ref]
8. Bondy SC, Guo-Ross SX, Truong AT. Promotion of transition metal-induced reactive oxygen species formation by beta-amyloid. Brain Res. 1998;799:91–6. doi: 10.1016/S0006-8993(98)00461-2. [PubMed] [Cross Ref]
9. Huang X, Atwood CS, Hartshorn MA, Multhaup G, Goldstein LE, Scarpa RC, Cuajungco MP, Gray DN, Lim J, Moir RD, Tanzi RE, Bush AI. The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry (Mosc) 1999;38:7609–16. doi: 10.1021/bi990438f. [PubMed] [Cross Ref]
10. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, Smith MA. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the ‘two hit’ hypothesis. Mech Ageing Dev. 2001;123:39–46. doi: 10.1016/S0047-6374(01)00342-6. [PubMed] [Cross Ref]
11. Zhu X, Lee HG, Perry G, Smith MA. Alzheimer disease, the two-hit hypothesis: an update. Biochim Biophys Acta. 2007;1772:494–502. [PubMed]
12. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 2004;3:219–26. doi: 10.1016/S1474-4422(04)00707-0. [PubMed] [Cross Ref]
13. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201. doi: 10.1016/j.neuron.2008.01.003. [PubMed] [Cross Ref]
14. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809–14. doi: 10.1212/01.wnl.0000262031.18018.1a. [PMC free article] [PubMed] [Cross Ref]
15. Shah S, Reichman WE. Treatment of Alzheimer's disease across the spectrum of severity. Clin Interv Aging. 2006;1:131–42. doi: 10.2147/ciia.2006.1.2.131. [PMC free article] [PubMed] [Cross Ref]
16. Cummings JL, Frank JC, Cherry D, Kohatsu ND, Kemp B, Hewett L, Mittman B. Guidelines for managing Alzheimer's disease: part II. treatment. Am Fam Physician. 2002;65:2525–34. [PubMed]
17. Munoz-Torrero D. Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem. 2008;15:2433–55. doi: 10.2174/092986708785909067. [PubMed] [Cross Ref]
18. Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf. 2008;31:577–85. doi: 10.2165/00002018-200831070-00003. [PubMed] [Cross Ref]
19. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006:CD003476. [PubMed]
20. Grossman F, Okamoto A, Turkoz I, Gharabawi G. Risperidone in the treatment of elderly patients with psychosis of Alzheimer's disease and related dementias. J Am Geriatr Soc. 2004;52:852–3. doi: 10.1111/j.1532-5415.2004.52230_12.x. [PubMed] [Cross Ref]
21. Salzman C. Treatment of the agitation of late-life psychosis and Alzheimer's disease. Eur Psychiatry. 2001;16(1):25s–28s. doi: 10.1016/S0924-9338(00)00525-3. [PubMed] [Cross Ref]
22. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, Normand SL, Gurwitz JH, Marras C, Wodchis WP, Mamdani M. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ. 2005;330:445. doi: 10.1136/bmj.38330.470486.8F. [PMC free article] [PubMed] [Cross Ref]
23. Attard A, Ranjith G, Taylor D. Delirium and its treatment. CNS Drugs. 2008;22:631–44. doi: 10.2165/00023210-200822080-00002. [PubMed] [Cross Ref]
24. Karlsson I. Drugs that induce delirium. Dement Geriatr Cogn Disord. 1999;10:412–5. doi: 10.1159/000017180. [PubMed] [Cross Ref]
25. Wada K, Ishigaki S, Ueda K, Take Y, Sasaki K, Sakata M, Haga M. Studies on the constitution of edible and medicinal plants. I. Isolation and identification of 4-O-methylpyridoxine, toxic principle from the seed of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 1988;36:1779–82. [PubMed]
26. Oyama Y, Fuchs PA, Katayama N, Noda K. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 1994;635:125–9. doi: 10.1016/0006-8993(94)91431-1. [PubMed] [Cross Ref]
27. DeFeudis F. Ginkgo Biloba Extract (Egb761) Pharmacological Act and Clinical Application. Paris: Elsevier; 1991.
28. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216–22. doi: 10.1056/NEJM199704243361704. [PubMed] [Cross Ref]
29. Jama JW, Launer LJ, Witteman JC, den Breeijen JH, Breteler MM, Grobbee DE, Hofman A. Dietary antioxidants and cognitive function in a population-based sample of older persons. The Rotterdam Study. Am J Epidemiol. 1996;144:275–80. [PubMed]
30. Perrig WJ, Perrig P, Stähelin HB. The relation between antioxidants and memory performance in the old and very old. J Am Geriatr Soc. 1997;45:718–24. [PubMed]
31. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008:CD002854. [PubMed]
32. Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA, Perry G, Nakamura M. Lipid peroxidation and 4-hydroxy-2-nonenal formation by copper ion bound to amyloid-beta peptide. Free Radic Biol Med. 2007;43:1552–9. doi: 10.1016/j.freeradbiomed.2007.08.013. [PubMed] [Cross Ref]
33. Nakamura M, Shishido N, Nunomura A, Smith MA, Perry G, Hayashi Y, Nakayama K, Hayashi T. Three histidine residues of amyloid-beta peptide control the redox activity of copper and iron. Biochemistry (Mosc) 2007;46:12737–43. doi: 10.1021/bi701079z. [PubMed] [Cross Ref]
34. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci Lett. 2006;406:189–93. doi: 10.1016/j.neulet.2006.07.020. [PubMed] [Cross Ref]
35. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476–83. doi: 10.1056/NEJMoa011613. [PubMed] [Cross Ref]
36. Aisen PS, Jin S, Thomas RG, Sano M, Diaz-Arrastia R, Thal L, Alzheimer's Disease Cooperative Study NIA S3-02-01: ADCS homocysteine trial. Alzheimers Dement. 2007;3(1):S199.
37. Viswanathan A, Raj S, Greenberg SM, Stampfer M, Campbell S, Hyman BT, Irizarry MC. Plasma Abeta, homocysteine, and cognition: the Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology. 2009;72:268–72. doi: 10.1212/01.wnl.0000339486.63862.db. [PMC free article] [PubMed] [Cross Ref]
38. Casadesus G, Webber KM, Atwood CS, Pappolla MA, Perry G, Bowen RL, Smith MA. Luteinizing hormone modulates cognition and amyloid-beta deposition in Alzheimer APP transgenic mice. Biochim Biophys Acta. 2006;1762:447–52. [PubMed]
39. Greco SJ, Sarkar S, Johnston JM, Zhu X, Su B, Casadesus G, Ashford JW, Smith MA, Tezapsidis N. Leptin reduces Alzheimer's disease-related tau phosphorylation in neuronal cells. Biochem Biophys Res Commun. 2008;376:536–41. doi: 10.1016/j.bbrc.2008.09.026. [PMC free article] [PubMed] [Cross Ref]
40. Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738–45. doi: 10.1176/appi.ajp.159.5.738. [PubMed] [Cross Ref]
41. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17:27–45. doi: 10.2165/00023210-200317010-00003. [PubMed] [Cross Ref]
42. Risner ME, Saunders AM, Altman JF, Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford DA, Roses AD. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 2006;6:246–54. [PubMed]
43. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207–15. doi: 10.1016/S0140-6736(08)61074-0. [PubMed] [Cross Ref] F1000 Factor 3.0 Recommended
Evaluated by Elio Scarpini 28 Oct 2008
44. Wu S, Liang J, Miao D. Physical activity and cognitive function in Alzheimer disease. JAMA. 2009;301:273. doi: 10.1001/jama.2008.1011. author reply 273-74. [PubMed] [Cross Ref]
45. Castellani RJ, Lee HG, Zhu X, Nunomura A, Perry G, Smith MA. Neuropathology of Alzheimer disease: pathognomonic but not pathogenic. Acta Neuropathol (Berl) 2006;111:503–9. doi: 10.1007/s00401-006-0071-y. [PubMed] [Cross Ref]

Articles from F1000 Medicine Reports are provided here courtesy of Faculty of 1000 Ltd